Heirloom Wealth Management grew its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 52.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 211,886 shares of the company’s stock after purchasing an additional 73,171 shares during the period. Novo Nordisk A/S accounts for about 2.5% of Heirloom Wealth Management’s investment portfolio, making the stock its 16th largest position. Heirloom Wealth Management’s holdings in Novo Nordisk A/S were worth $10,781,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Beacon Financial Group lifted its stake in shares of Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares during the period. Kavar Capital Partners Group LLC grew its stake in Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after acquiring an additional 200 shares during the period. SeaBridge Investment Advisors LLC raised its holdings in Novo Nordisk A/S by 5.7% in the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after acquiring an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC lifted its stake in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 200 shares during the period. Finally, Revolve Wealth Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.
Novo Nordisk A/S Stock Up 4.0%
Shares of NYSE NVO opened at $36.71 on Wednesday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The firm has a fifty day moving average of $44.90 and a 200-day moving average of $50.16. The stock has a market capitalization of $163.90 billion, a PE ratio of 10.58, a P/E/G ratio of 8.35 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.
Novo Nordisk A/S Announces Dividend
The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 52.74%.
Wall Street Analyst Weigh In
Several equities analysts recently commented on NVO shares. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Finally, Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective on the stock in a report on Tuesday, March 3rd. Four analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $65.56.
Read Our Latest Stock Report on NVO
Trending Headlines about Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: UK cost‑effectiveness watchdog recommended use of Wegovy to reduce major heart risks in obese/overweight adults — the first GLP‑1 endorsed for this indication, which could broaden prescribing and boost long‑term demand. British drug-cost watchdog recommends use of Novo’s Wegovy to lower heart risks
- Positive Sentiment: Launched discounted multi‑month Wegovy subscriptions for U.S. self‑pay patients (up to ~30% off standard monthly rate) to improve access and predictable pricing — a defensive commercial move to regain share vs. Eli Lilly and to stabilize cash‑pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
- Positive Sentiment: Company is executing a share repurchase programme (part of a previously announced DKK 15bn plan), which supports EPS and signals management confidence in the business. Novo Nordisk A/S – share repurchase programme
- Positive Sentiment: Completed a key China study for a new obesity/diabetes candidate — clinical progress in large markets can materially increase future upside. Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion
- Positive Sentiment: Expanded distribution/affordability through partnerships (Hims telehealth GLP‑1 offering; Weight Watchers preferred pricing via NovoCare) — these broaden channels for self‑pay and insured patients. Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
- Neutral Sentiment: Company and rival Lilly are using AI across drug development to accelerate pipelines — a structural positive over the long term but not an immediate earnings driver. Lilly and Novo Show How AI Is Rewiring Big Pharma
- Negative Sentiment: Further deep price cuts in India for Ozempic and Wegovy (up to ~36–48%) to fend off local generics — helps retain volumes but pressures margins in a large market. Novo Nordisk further slashes prices of Ozempic, Wegovy in India
- Negative Sentiment: Planned layoffs at the Bloomington, Indiana manufacturing site (about 400 jobs) highlight cost‑cutting and operational reshaping; may be viewed negatively by some investors despite potential near‑term margin benefits. Novo Nordisk to lay off 400 Bloomington employees
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Recommended Stories
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
